User login
Dr. Howard A. "Skip" Burris III, editor-in-chief of The Oncology Report, and associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo wrap up their review of the 2012 San Antonio Breast Cancer Symposium with a discussion of everolimus use and anthracycline intensification in their practices. They also comment on a new CDK inhibitor, a trial comparing capecitabine and eribulin, and a study of neurocognitive effects after chemotherapy.
Dr. Howard A. "Skip" Burris III, editor-in-chief of The Oncology Report, and associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo wrap up their review of the 2012 San Antonio Breast Cancer Symposium with a discussion of everolimus use and anthracycline intensification in their practices. They also comment on a new CDK inhibitor, a trial comparing capecitabine and eribulin, and a study of neurocognitive effects after chemotherapy.
Dr. Howard A. "Skip" Burris III, editor-in-chief of The Oncology Report, and associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo wrap up their review of the 2012 San Antonio Breast Cancer Symposium with a discussion of everolimus use and anthracycline intensification in their practices. They also comment on a new CDK inhibitor, a trial comparing capecitabine and eribulin, and a study of neurocognitive effects after chemotherapy.
